Else Nutrition CEO Urges FDA to Expedite Approval of Plant-Based Infant Formula

Else Nutrition CEO, Hamutal Yitzhak, is urging the FDA to expedite the approval of plant-based infant formula alternatives. In an op-ed published in The Washington Times, Yitzhak highlighted the need for updated regulatory frameworks to accommodate novel nutrition products, especially those designed for infants with dietary restrictions or allergen sensitivities. The company is currently seeking FDA approval to initiate clinical trials for its plant-based infant formula, using ingredients like almonds, buckwheat, and tapioca as alternatives to traditional dairy- and soy-based products.

Else Nutrition has been actively engaging in lobbying efforts on Capitol Hill to advocate for updated infant formula guidelines and modernizing FDA regulations to include plant-based, non-soy, and allergen-friendly infant formulas. The company's efforts have contributed to Congressional oversight and calls for expedited regulatory modernization efforts. While Else Nutrition's product is not yet approved or available in the US market, the company has made progress by completing pre-clinical studies and receiving Institutional Review Board approval for its infant growth clinical study protocol, marking a step toward regulatory compliance.